nach oben

Tumor Biology

Erschienen in:

08.10.2016 | Review

Diverse roles of miR-335 in development and progression of cancers

verfasst von: Long-ji Luo, Dan-dan Wang, Jing Wang, Fan Yang, Jin-hai Tang

Erschienen in: Tumor Biology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

MicroRNAs (miRNAs), a series of small noncoding RNAs that regulate gene expression at the post-transcriptional/translational level, are pivotal in cell differentiation, biological development, occurrence, and development of diseases, especially in cancers. Early studies have shown that miRNA-335 (miR-335) is widely dysregulated in human cancers and play critical roles in tumorigenesis and tumor progression. In this review, we aim to summarize the regulation of miR-335 expression mechanisms in cancers. We focus on the target genes regulated by miR-335 and its downstream signaling pathways involved in the biological effects of tumor growth, invasion, and metastasis both in vitro and in vivo, and analyze the relationships between miR-335 expression and the clinical characteristics of tumors as well as its effects on prognosis. The collected evidences support the potential use of miR-335 in prognosis and diagnosis as well as the therapeutic prospects of miR-335 in cancers.

Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.PubMedPubMedCentralCrossRef

He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31.PubMedCrossRef

Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597–610.PubMed

Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012;13(5):358–69.PubMedPubMedCentralCrossRef

Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105.PubMedPubMedCentralCrossRef

Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.PubMedCrossRef

Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115(7):787–98.PubMedCrossRef

Gunaratne PH, Creighton CJ, Watson M, Tennakoon JB. Large-scale integration of MicroRNA and gene expression data for identification of enriched microRNA-mRNA associations in biological systems. Methods Mol Biol. 2010;667:297–315.PubMedCrossRef

Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in drosophila. Cell. 2003;113(1):25–36.PubMedCrossRef

10.

Xu P, Vernooy SY, Guo M, Hay BA. The drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol. 2003;13(9):790–5.PubMedCrossRef

11.

Kawasaki H, Taira K. Hes1 is a target of microRNA-23 during retinoic-acid-induced neuronal differentiation of NT2 cells. Nature. 2003;423(6942):838–42.PubMedCrossRef

12.

Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403(6772):901–6.PubMedCrossRef

13.

Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. MicroRNAs in cancer management. Kong YW, Ferland-McCollough D, Jackson TJ, et al. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249–58.PubMedCrossRef

14.

Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.PubMedCrossRef

15.

Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Ventura a, jacks T, MicroRNAs and cancer: short RNAs go a long way. Cell. 2009;136(4):586–91.PubMedPubMedCentralCrossRef

16.

Shi L, Jiang D, Sun G, Wan Y, Zhang S, Zeng Y, et al. miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. J Neuro-Oncol. 2012;110(2):155–62. doi:10.1007/s11060-012-0951-z.CrossRef

17.

Fu Q, Liu X, Liu Y, Yang J, Lv G, Dong S. MicroRNA-335 and −543 suppress bone metastasis in prostate cancer via targeting endothelial nitric oxide synthase. Int J Mol Med. 2015;36(5):1417–25. doi:10.3892/ijmm.2015.2355.PubMed

18.

Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147–52. doi:10.1038/nature06487.PubMedPubMedCentralCrossRef

19.

Sun Z, Zhang Z, Liu Z, Qiu B, Liu K, Dong G. MicroRNA-335 inhibits invasion and metastasis of colorectal cancer by targeting ZEB2. Med Oncol. 2014;31(6):982. doi:10.1007/s12032-014-0982-8.PubMedCrossRef

20.

Dohi O, Yasui K, Gen Y, Takada H, Endo M, Tsuji K, et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol. 2013;42(2):411–8. doi:10.3892/ijo.2012.1724.PubMed

21.

Heyn H, Engelmann M, Schreek S, Ahrens P, Lehmann U, Kreipe H, et al. MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer. 2011;129(12):2797–806. doi:10.1002/ijc.25962.PubMedCrossRef

22.

Gao Y, Zeng F, JY W, Li HY, Fan JJ, Mai L, et al. MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-met. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015;36(4):2875–83. doi:10.1007/s13277-014-2917-6.CrossRef

23.

Ronchetti D, Lionetti M, Mosca L, Agnelli L, Andronache A, Fabris S, et al. An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genet. 2008;1:37. doi:10.1186/1755-8794-1-37.

24.

Kozaki K, Inazawa J. Tumor-suppressive microRNA silenced by tumor-specific DNA hypermethylation in cancer cells. Cancer Sci. 2012;103(5):837–45. doi:10.1111/j.1349-7006.2012.02236.x.PubMedCrossRef

25.

Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A, et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev. 2011;25(3):226–31. doi:10.1101/gad.1974211.PubMedPubMedCentralCrossRef

26.

Li Z, Li D, Zhang G, Xiong J, Jie Z, Cheng H, et al. Methylation-associated silencing of MicroRNA-335 contributes tumor cell invasion and migration by interacting with RASA1 in gastric cancer. Am J Cancer Res. 2014;4(6):648–62.PubMedPubMedCentral

27.

Zhang S, Kim K, Jin UH, Pfent C, Cao H, Amendt B, et al. Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells. Mol Cancer Ther. 2012;11(1):108–18. doi:10.1158/1535-7163.MCT-11-0548.PubMedCrossRef

28.

Heidary MF, Mahmoodzadeh Hosseini H, Mehdizadeh Aghdam E, Nourani MR, Ranjbar R, Mirnejad R, et al. Overexpression of metastatic related MicroRNAs, Mir-335 and Mir-10b, by staphylococcal enterotoxin B in the metastatic breast cancer cell line. Advanced pharmaceutical bulletin. 2015;5(2):255–9. doi:10.15171/apb.2015.035.PubMedPubMedCentralCrossRef

29.

Lynch J, Fay J, Meehan M, Bryan K, Watters KM, Murphy DM, et al. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis. 2012;33(5):976–85. doi:10.1093/carcin/bgs114.PubMedPubMedCentralCrossRef

30.

Qiao J, Lee S, Paul P, Theiss L, Tiao J, Qiao L, et al. miR-335 and miR-363 regulation of neuroblastoma tumorigenesis and metastasis. Surgery. 2013;154(2):226–33. doi:10.1016/j.surg.2013.04.005.PubMedPubMedCentralCrossRef

31.

Qiao J, Lee S, Paul P, Qiao L, Taylor CJ, Schlegel C, et al. Akt2 regulates metastatic potential in neuroblastoma. PLoS One. 2013;8(2).

32.

Sankar N, Baluchamy S, Kadeppagari RK, Singhal G, Weitzman S, Thimmapaya B. p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-myc. Oncogene. 2008;27(43):5717–28.PubMedCrossRef

33.

Kim Y, Kim H, Park H, Park D, Lee H, Lee YS, et al. miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J Biol Chem. 2014;289(40):28019–39. doi:10.1074/jbc.M114.578229.PubMedPubMedCentralCrossRef

34.

Du L, Sun W, Zhang H, Chen D. BDE-209 inhibits pluripotent genes expression and induces apoptosis in human embryonic stem cells. Journal of applied toxicology: JAT. 2015. doi:10.1002/jat.3195.

35.

Shu M, Zhou Y, Zhu W, Zhang H, Wu S, Chen J, et al. MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase a pathway. Mol Pharmacol. 2012;81(3):292–8. doi:10.1124/mol.111.076166.PubMedCrossRef

36.

Scarola M, Schoeftner S, Schneider C, Benetti R. miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response. Cancer Res. 2010;70(17):6925–33. doi:10.1158/0008-5472.CAN-10-0141.PubMedCrossRef

37.

Martin NT, Nakamura K, Davies R, Nahas SA, Brown C, Tunuguntla R, et al. ATM-dependent MiR-335 targets CtIP and modulates the DNA damage response. PLoS Genet. 2013;9(5):e1003505. doi:10.1371/journal.pgen.1003505.PubMedPubMedCentralCrossRef

38.

Woods A, Wang G, Beier F. RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis. J Biol Chem. 2005;280(12):11626–34.PubMedCrossRef

39.

Lin X, Wu L, Zhang Z, Yang R, Guan Q, Hou X, et al. MiR-335-5p promotes chondrogenesis in mouse mesenchymal stem cells and is regulated through two positive feedback loops. J Bone Miner Res Off J Am Soc Bone Miner Res. 2014;29(7):1575–85. doi:10.1002/jbmr.2163.CrossRef

40.

Tome M, Lopez-Romero P, Albo C, Sepulveda JC, Fernandez-Gutierrez B, Dopazo A, et al. miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ. 2011;18(6):985–95. doi:10.1038/cdd.2010.167.PubMedCrossRef

41.

Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, et al. p14ARF links the tumour suppressors RB and p53. Nature. 1998;395(6698):124–5.PubMedCrossRef

42.

Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006;444(7115):61–6.PubMedCrossRef

43.

Zhang J, Pickering CR, Holst CR, Gauthier ML, Tlsty TD. p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res. 2006;66(21):10325–31.PubMedCrossRef

44.

Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19(1):128–39.PubMedPubMedCentralCrossRef

45.

Li X, Miyajima M, Jiang C, Arai H. Expression of TGF-betas and TGF-beta type II receptor in cerebrospinal fluid of patients with idiopathic normal pressure hydrocephalus. Neurosci Lett. 2007;413(2):141–4.PubMedCrossRef

46.

Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang X, et al. MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 2012;31(11):1398–407. doi:10.1038/onc.2011.340.PubMedCrossRef

47.

Hiraga T, Myoui A, Hashimoto N, Sasaki A, Hata K, Morita Y, et al. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res. 2012;72(16):4238–49.PubMedPubMedCentralCrossRef

48.

Lynch J, Meehan MH, Crean J, Copeland J, Stallings RL, Bray IM. Metastasis suppressor microRNA-335 targets the formin family of actin nucleators. PLoS One. 2013;8(11):e78428. doi:10.1371/journal.pone.0078428.PubMedPubMedCentralCrossRef

49.

Shu M, Zheng X, Wu S, Lu H, Leng T, Zhu W, et al. Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Mol Cancer. 2011;10(59):1476–4598.

50.

Li H, Xie S, Liu M, Chen Z, Liu X, Wang L, et al. The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol. 2014;45(1):197–208. doi:10.3892/ijo.2014.2415.PubMed

51.

Erturk E, Cecener G, Egeli U, Tunca B, Tezcan G, Gokgoz S, et al. Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations. Mol Cell Biochem. 2014;395(1–2):77–88. doi:10.1007/s11010-014-2113-4.PubMedCrossRef

52.

Yan Z, Xiong Y, Xu W, Gao J, Cheng Y, Wang Z, et al. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One. 2012;7(7).

53.

Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009;23(18):2152–65.PubMedPubMedCentralCrossRef

54.

Yang W, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol. 2011;3(2):140–55.PubMed

55.

Polytarchou C, Iliopoulos D, Struhl K. An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci U S A. 2012;109(36):14470–5.PubMedPubMedCentralCrossRef

56.

Cheng Q, Cao H, Chen Z, Ma Z, Wan X, Peng R, et al. PAX6, a novel target of miR-335, inhibits cell proliferation and invasion in glioma cells. Mol Med Rep. 2014;10(1):399–404. doi:10.3892/mmr.2014.2150.PubMed

57.

Zu Y, Ban J, Xia Z, Wang J, Cai Y, Ping W, et al. Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations. Biochem Biophys Res Commun. 2013;430(2):529–34. doi:10.1016/j.bbrc.2012.12.001.PubMedCrossRef

58.

Yang B, Huang J, Liu H, Guo W, Li G. miR-335 directly, while miR-34a indirectly modulate survivin expression and regulate growth, apoptosis, and invasion of gastric cancer cells. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015. doi:10.1007/s13277-015-3951-8.

59.

Liu H, Li W, Chen C, Pei Y, Long X. MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015;36(8):6313–9. doi:10.1007/s13277-015-3317-2.CrossRef

60.

Wang H, Li M, Zhang R, Wang Y, Zang W, Ma Y, et al. Effect of miR-335 upregulation on the apoptosis and invasion of lung cancer cell A549 and H1299. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013;34(5):3101–9. doi:10.1007/s13277-013-0878-9.CrossRef

61.

Wang K, Chen X, Zhan Y, Jiang W, Liu X, Wang X, et al. miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of BCL-W. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015;36(9):6875–82. doi:10.1007/s13277-015-3382-6.CrossRef

62.

Gong M, Ma J, Guillemette R, Zhou M, Yang Y, Yang Y, et al. miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Molecular cancer research: MCR. 2014;12(1):101–10. doi:10.1158/1541-7786.MCR-13-0136.PubMedCrossRef

63.

Xiong SW, Lin TX, KW X, Dong W, Ling XH, Jiang FN, et al. MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer. Pathol Oncol Res. 2013;19(3):529–37.PubMedCrossRef

64.

Gao L, Yang Y, Xu H, Liu R, Li D, Hong H, et al. MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(8):8309–18. doi:10.1007/s13277-014-2092-9.CrossRef

65.

Alfano D, Gorrasi A, Li Santi A, Ricci P, Montuori N, Selleri C, et al. Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells. J Cell Mol Med. 2015;19(9):2262–72. doi:10.1111/jcmm.12617.PubMedPubMedCentral

66.

Catrina Ene AM, Borze I, Guled M, Costache M, Leen G, Sajin M, et al. MicroRNA expression profiles in Kaposi’s sarcoma. Pathol Oncol Res. 2014;20(1):153–9. doi:10.1007/s12253-013-9678-1.PubMedCrossRef

67.

Li G, MicroRNA PY. Signatures in total peripheral blood of gallbladder cancer patients. Tumour biology: the journal of the international society for. Oncodevelopmental Biology and Medicine. 2015;36(9):6985–90. doi:10.1007/s13277-015-3412-4.CrossRef

68.

Berx G, Raspé E, Christofori G, Thiery JP, Sleeman JP. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Berx G, Raspé E, Christofori G, et al. pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis. 2007;24(8):587–97.PubMedCrossRef

69.

Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nguyen DX, Bos PD, Massagué J, metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–84.PubMedCrossRef

70.

Spaderna S, Schmalhofer O, Hlubek F, Jung A, Kirchner T, Brabletz T. Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Spaderna S, Schmalhofer O, Hlubek F, et al. epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Verh Dtsch Ges Pathol. 2007:9121–8.

71.

Varki A, Varki NM, Borsig L. Molecular basis of metastasis. Varki a, Varki NM, Borsig L, molecular basis of metastasis. N Engl J Med. 2009;360(16):1678–9 .author reply 1679-80PubMedCrossRef

72.

Bae IH, Park MJ, Yoon SH, Kang SW, Lee SS, Choi KM, et al. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res. 2006;66(10):4991–5.PubMedCrossRef

73.

Wang Y, Zhao W, Fu Q. miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells. Mol Cell Biochem. 2013;384(1–2):105–11. doi:10.1007/s11010-013-1786-4.PubMedCrossRef

74.

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Thiery JP, Acloque H, Huang RY, et al. epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.PubMedCrossRef

75.

Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001;7(6):1267–78.PubMedCrossRef

76.

Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415–28.PubMedCrossRef

77.

Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res. 2005;33(20):6566–78.PubMedPubMedCentralCrossRef

78.

Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res. 2010;16(4):1094–9.PubMedPubMedCentralCrossRef

79.

Tocque B, Delumeau I, Parker F, Maurier F, Multon MC, Schweighoffer F. Ras-GTPase activating protein (GAP): a putative effector for Ras. Cell Signal. 1997;9(2):153–8.PubMedCrossRef

80.

Lu Y, Yang H, Yuan L, Liu G, Zhang C, Hong M, et al. Overexpression of miR-335 confers cell proliferation and tumour growth to colorectal carcinoma cells. Mol Cell Biochem. 2015;412(1–2):235–45. doi:10.1007/s11010-015-2630-9.PubMed

81.

Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Kessenbrock K, Plaks V, Werb Z, matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.PubMedPubMedCentralCrossRef

82.

Li D, Hallett MA, Zhu W, Rubart M, Liu Y, Yang Z, et al. Dishevelled-associated activator of morphogenesis 1 (Daam1) is required for heart morphogenesis. Development. 2011;138(2):303–15.PubMedPubMedCentralCrossRef

83.

Rojas F, Hernandez ME, Silva M, Li L, Subramanian S, Wilson MJ, et al. The oncogenic response to MiR-335 is associated with cell surface expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) activity. PLoS One. 2015;10(7):e0132026. doi:10.1371/journal.pone.0132026.PubMedPubMedCentralCrossRef

84.

Gingras D, Beliveau R. Emerging concepts in the regulation of membrane-type 1 matrix metalloproteinase activity. Biochim Biophys Acta. 2010;1:142–50.CrossRef

85.

D’Alessio S, Ferrari G, Cinnante K, Scheerer W, Galloway AC, Roses DF, et al. Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J Biol Chem. 2008;283(1):87–99.PubMedCrossRef

86.

Lin X, Wang Z, Zhang R, Feng W. High serum microRNA-335 level predicts aggressive tumor progression and unfavorable prognosis in pediatric acute myeloid leukemia. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2015;17(5):358–64. doi:10.1007/s12094-014-1237-z.CrossRef

87.

Bao B, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, et al. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Stem Cells Dev. 2014;23(16):1947–58. doi:10.1089/scd.2013.0551.PubMedCrossRef

88.

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.PubMedCrossRef

89.

Yang R, Dick M, Marme F, Schneeweiss A, Langheinz A, Hemminki K, et al. Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast Cancer Res Treat. 2011;127(2):549–54. doi:10.1007/s10549-010-1244-x.PubMedCrossRef

90.

Hafez MM, Hassan ZK, Zekri ARN, Gaber AA, Rejaie SSA, Sayed-Ahmed MM, et al. MicroRNAs and metastasis-related Gene expression in Egyptian breast cancer patients. Asian Pac J Cancer Prev. 2012;13(2):591–8. doi:10.7314/apjcp.2012.13.2.591.PubMedCrossRef

91.

Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2013;25(1):46–54. doi:10.3978/j.issn.1000-9604.2012.11.04.PubMedPubMedCentral

92.

Vickers MM, Bar J, Gorn-Hondermann I, Yarom N, Daneshmand M, Hanson JE, et al. Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clinical & experimental metastasis. 2012;29(2):123–32. doi:10.1007/s10585-011-9435-3.CrossRef

93.

Cui L, Hu Y, Bai B, Zhang S. Serum miR-335 level is associated with the treatment response to trans-arterial chemoembolization and prognosis in patients with hepatocellular carcinoma. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2015;37(1):276–83. doi:10.1159/000430352.CrossRef

94.

Slattery ML, Herrick JS, Mullany LE, Valeri N, Stevens J, Caan BJ, et al. An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. International journal of cancer Journal international du cancer. 2015;137(2):428–38. doi:10.1002/ijc.29384.PubMedCrossRef

95.

Peng HH, Zhang YD, Gong LS, Liu WD, Zhang Y. Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma. OncoTargets and therapy. 2013;6:1625–30. doi:10.2147/OTT.S53030.PubMedPubMedCentral

96.

Schmitz KJ, Helwig J, Bertram S, Sheu SY, Suttorp AC, Seggewiss J, et al. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol. 2011;64(6):529–35. doi:10.1136/jcp.2010.085621.PubMedPubMedCentralCrossRef

97.

Chabre O, Libe R, Assie G, Barreau O, Bertherat J, Bertagna X, et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocrine-related cancer. 2013;20(4):579–94. doi:10.1530/ERC-13-0051.PubMed

98.

Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res. 2009;15(24):7684–92. doi:10.1158/1078-0432.CCR-09-1587.PubMedCrossRef

99.

Jiang J, Sun X, Wang W, Jin X, Bo X, Li Z, et al. Tumor microRNA-335 expression is associated with poor prognosis in human glioma. Med Oncol. 2012;29(5):3472–7. doi:10.1007/s12032-012-0259-z.PubMedCrossRef

100.

Ma J, Li N, Guarnera M, Jiang F. Quantification of plasma miRNAs by digital PCR for cancer diagnosis. Biomark Insights. 2013;8:127–36. doi:10.4137/BMI.S13154.PubMedPubMedCentral

101.

Zhang BJ, Gong HY, Zheng F, Liu DJ, Liu HX. Up-regulation of miR-335 predicts a favorable prognosis in esophageal squamous cell carcinoma. Zhang BJ, gong HY, Zheng F, et al. up-regulation of miR-335 predicts a favorable prognosis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7(9):6213–8.PubMedPubMedCentral

102.

Yingchun L, Rong Z, Kun Y, Ying Y, Zhuogang L. Bone marrow MicroRNA-335 level predicts the chemotherapy response and prognosis of adult acute myeloid leukemia. Medicine. 2015;94(33):e0986. doi:10.1097/MD.0000000000000986.PubMedPubMedCentralCrossRef

103.

Wang C, Jiang T. MicroRNA-335 represents an independent prognostic marker in cervical cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015;36(8):5825–30. doi:10.1007/s13277-015-3252-2.CrossRef

104.

Cao J, Cai J, Huang D, Han Q, Chen Y, Yang Q, et al. miR-335 represents an independent prognostic marker in epithelial ovarian cancer. Am J Clin Pathol. 2014;141(3):437–42. doi:10.1309/AJCPLYTZGB54ISZC.PubMedCrossRef

105.

Hu H, Zhang Y, Cai XH, Huang JF, Cai L. Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts. Oncol Lett. 2012;4(5):1037–42. doi:10.3892/ol.2012.866.PubMedPubMedCentral

Titel: Diverse roles of miR-335 in development and progression of cancers
verfasst von: Long-ji Luo
Dan-dan Wang
Jing Wang
Fan Yang
Jin-hai Tang
Publikationsdatum: 08.10.2016
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 12/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5385-3

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Diverse roles of miR-335 in development and progression of cancers

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2016

Reduced decorin expression in the tumor stroma correlates with tumor proliferation and predicts poor prognosis in patients with I–IIIA non-small cell lung cancer

Suppression of CD26 inhibits growth and metastasis of pancreatic cancer

Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms

Chloroquine inhibits tumor growth and angiogenesis in malignant pleural effusion

Retraction Note to: Downregulation of microRNA-217 and microRNA-646 acts as potential predictor biomarkers in progression, metastasis, and unfavorable prognosis of human osteosarcoma

Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie